- Autonomix Medical, Inc. (AMIX, Financial) announces inducement stock option grant under Nasdaq Rule 5635(c)(4).
- Grant allows for the purchase of 5,000 shares with a ten-year term, set to vest in four annual installments.
- The grant is part of compensation for a new non-executive employee, linked to employment continuation.
Autonomix Medical, Inc. (AMIX), a pioneering medical device company specializing in the diagnosis and treatment of nervous system diseases, has initiated a new inducement stock option grant. Approved by the company's Compensation Committee on April 17, 2025, this grant permits a new non-executive employee to acquire up to 5,000 shares of Autonomix's common stock.
The exercise price for these options is based on Autonomix's closing stock price as reported on the Nasdaq Capital Market on the same date. The stock options are structured with a ten-year term and will vest in four equal annual installments, contingent upon the employee’s continued service with the company through each vesting date. This initiative is part of the employment compensation package under Nasdaq Rule 5635(c)(4).
Autonomix Medical is actively developing advanced technologies designed to improve the diagnosis and treatment of diseases affecting the nervous system. The company’s innovative platform uses catheter-based microchip sensing array technology, which may potentially offer better sensitivity in detecting neural signals. This could enable new methods for diagnosing and treating peripheral nervous system diseases, with initial applications targeting pain management in conditions like pancreatic cancer.
